Man Group’s Harvard Bioscience HBIO Stock Holding History

Man Group’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,773	Closed	-$97.3K	–	2007
2023 Q2	$97.3K	Buy	+1,773	New	+$97.3K	﹤0.01%	1883
2023 Q1	–	Sell	-4,097	Closed	-$122K	–	1976
2022 Q4	$113K	Buy	4,097 +1,663	+68%	+$41K	﹤0.01%	1889
2022 Q3	$62K	Buy	+2,434	New	+$80.5K	﹤0.01%	1882
2022 Q2	–	Hold	0	–	–	–	1963

Other funds holding HBIO

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Man Group's HBIO Position: Q3 2023 in Review

Man Group sold out of Harvard Bioscience (HBIO) in Q3 2023, closing a stake of 1,773 shares — an estimated $97.3K sold.

Man Group first reported a position in HBIO in Q3 2022 and held it in 3 quarters. The position peaked at $113K in Q4 2022. 94 funds tracked by Wall St. Rank hold HBIO as of Q3 2023.

Man Group reported no remaining Harvard Bioscience position as of Q3 2023 after selling out during the quarter.
Man Group sold 1,773 Harvard Bioscience shares in Q3 2023, an estimated $97.3K.
Man Group first reported a position in Harvard Bioscience in Q3 2022 and held it in 3 quarters.
Man Group's Harvard Bioscience position peaked at $113K in Q4 2022.
94 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2023.

Based on Man Group's 13F filing for Q3 2023, filed 14 Nov 2023.